Medical inquiries

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

RYBREVANT® (amivantamab-vmjw)

Medical Information

+ Save link

RYBREVANT – Vial Overfill

Last Updated: 05/06/2024

SUMMARY

Each single-dose RYBREVANT vial contains 350 mg/7mL (50 mg/mL)
amivantamab-vmjw in an 8 mL glass vial with a target fill of 7.5 mL.¹^,²
Discard any unused portion left in the vial.²
Please refer to the DOSAGE AND ADMINISTRATION section of the full Prescribing Information.²

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 02 May 2024.

References

Show

1	Data on File. Amivantamab Drug Product Formulation Development. Janssen Research & Development, LLC. EDMS-ERI-186630376; 2020.
2	RYBREVANT (amivantamab-vmjw) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.;https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf.